Fluorodeoxyglucose positron emission tomography and chemotherapy-related tumor marker expression in non-small cell lung cancer

BMC Cancer

You-Min Guo¹  Jun-Gang Gao¹  Jin Shang¹  Jian-Sheng Wang²  Wen Wang¹  Xiao-Yi Duan¹ 

[1]PET-CT Center, the First Affiliated Hospital, Medical School, Xi’an Jiaotong University, No.277 West Yanta road, Xi’an, Shaanxi 710061, People’s Republic of China

[2]Department of Oncology, the First Affiliated Hospital, Medical School, Xi’an Jiaotong University, No.277 West Yanta road, Xi’an, Shaanxi 710061, People’s Republic of China

关键词: Fluorodeoxyglucose positron emission tomography (FDG–PET);    Tumor markers;    Non–small cell lung cancer;   

Others  :  859252
DOI  :  10.1186/1471-2407-13-546

 received in 2013-06-27, accepted in 2013-11-08,  发布年份 2013

【 摘 要 】

Background

The chemotherapy resistance of non-small cell lung cancer (NSCLC) remains a clinic challenge and is closely associated with several biomarkers including epidermal growth factor receptor (EGFR) ( Drugs 72(Suppl 1):28–36, 012.), p53 ( Med Sci Monit 11(6):HY11–HY20, 2005.) and excision repair cross complementing gene 1 (ERCC1) ( J Thorac Oncol 8(5):582–586, 2013.). Fluorodeoxyglucose positron emission tomography (FDG–PET) is the best non-invasive surrogate for tumor biology with the maximal standardized uptake values (SUV_max) being the most important paradigm. However, there are limited data correlating FDG-PET with the chemotherapy resistant tumor markers. The purpose of this study was to determine the correlation of chemotherapy related tumor marker expression with FDG–PET SUV_max in NSCLC.

Methods

FDG–PET SUV_max was calculated in chemotherapy naïve patients with NSCLC (n = 62) and immunohistochemical analysis was performed for EGFR, p53 or ERCC1 on the intraoperative NSCLC tissues. Each tumor marker was assessed independently by two pathologists using common grading criteria. The SUV_max difference based on the histologic characteristics, gender, differentiation, grading and age as well as correlation analysis among these parameters were performed. Multiple stepwise regression analysis was further performed to determine the primary predictor for SUV_max and the receiver operating characteristics (ROC) curve analysis was performed to detect the optimized sensitivity and specificity for SUV_max in suggesting chemotherapy resistant tumor markers.

Results

The significant tumor type (P = 0.045), differentiation (P = 0.021), p53 (P = 0.000) or ERCC1 (P = 0.033) positivity dependent differences of SUV_max values were observed. The tumor differentiation is significantly correlated with SUV_max (R = -0.327), tumor size (R = -0.286), grading (R = -0.499), gender (R = 0.286) as well as the expression levels for p53 (R = -0.605) and ERCC1 (R = -0.644). The expression level of p53 is significantly correlated with SUV_max (R = 0.508) and grading (R = 0.321). Furthermore, multiple stepwise regression analysis revealed that p53 expression was the primary predictor for SUV_max. When the cut-off value of SUV_max was set at 5.15 in the ROC curve analysis, the sensitivity and specificity of SUV_max in suggesting p53 positive NSCLC were 79.5% and 47.8%, respectively.

Conclusion

The current study suggests that SUV_max of primary tumor on FDG-PET might be a simple and good non-invasive method for predicting p53-related chemotherapy resistance in NSCLC when we set the cu-off value of SUVmax at 5.15.

【 授权许可】

   
2013 Duan et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al.: Cancer treatment and survivorship statistics, 2012. CA 2012, 62(4):220-241.
• [2]Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proc 2008, 83(5):584-594.
• [3]Yuan K, Qian C, Zheng R: Prognostic significance of immunohistochemical Rac1 expression in survival in early operable non-small cell lung cancer. Med Sci Monit 2009, 15(11):BR313-BR319.
• [4]Saisho S, Yasuda K, Maeda A, Yukawa T, Okita R, Hirami Y, Shimizu K, Nakata M: Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy. Interact Cardiovasc Thorac Surg 2013, 16(2):166-172.
• [5]Booth CM, Shepherd FA, Peng Y, Darling G, Li G, Kong W, Biagi JJ, Mackillop WJ: Time to adjuvant chemotherapy and survival in non-small cell lung cancer: a population-based study. Cancer 2013, 119(6):1243-1250.
• [6]Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, International Adjuvant Lung Cancer Trial Collaborative G: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350(4):351-360.
• [7]Alam N, Shepherd FA, Winton T, Graham B, Johnson D, Livingston R, Rigas J, Whitehead M, Ding K, Seymour L: Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer 2005, 47(3):385-394.
• [8]Stewart DJ, Chiritescu G, Dahrouge S, Banerjee S, Tomiak EM: Chemotherapy dose–response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev 2007, 33(2):101-137.
• [9]d'Amato TA, Landreneau RJ, McKenna RJ, Santos RS, Parker RJ: Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer. Ann Thorac Surg 2006, 81(2):440-446. discussion 446–447
• [10]Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Storkel S, et al.: EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012, 13(1):33-42.
• [11]D’Amato TA, Landreneau RJ, Ricketts W, Huang W, Parker R, Mechetner E, Yu IR, Luketich JD: Chemotherapy resistance and oncogene expression in non-small cell lung cancer. J Thorac Cardiovasc Surg 2007, 133(2):352-363.
• [12]Simon GR, Ismail-Khan R, Bepler G: Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J BiochemCell Biol 2007, 39(7–8):1318-1328.
• [13]Furukawa H, Ikuma H, Asakura K, Uesaka K: Prognostic importance of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma. J Surg Oncol 2009, 100(6):494-499.
• [14]Higashi K, Ueda Y, Sakurai A, Wang XM, Xu L, Murakami M, Seki H, Oguchi M, Taki S, Nambu Y, et al.: Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med 2000, 27(12):1778-1785.
• [15]Shimizu K, Hirami Y, Saisho S, Yukawa T, Maeda A, Yasuda K, Nakata M: Maximal standardized uptake value on FDG-PET is correlated with cyclooxygenase-2 expression in patients with lung adenocarcinoma. Ann Thorac Surg 2012, 93(2):398-403.
• [16]Watanabe K, Nomori H, Ohtsuka T, Naruke T, Ebihara A, Orikasa H, Yamazaki K, Uno K, Kobayashi T, Goya T: [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. Jpn J Clin Oncol 2006, 36(7):403-409.
• [17]Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, et al.: Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. Cancer Sci 2009, 100(4):753-758.
• [18]Gibbs AR, Thunnissen FB: Histological typing of lung and pleural tumours: third edition. J Clin Pathol 2001, 54(7):498-499.
• [19]Rankin S: PET/CT for staging and monitoring non small cell lung cancer. Cancer Imaging 2008, 8(A):S27-S31.
• [20]Koksal D, Demirag F, Bayiz H, Ozmen O, Tatci E, Berktas B, Aydogdu K, Yekeler E: The correlation of SUVmax with pathological characteristics of primary tumor and the value of Tumor/ Lymph node SUVmax ratio for predicting metastasis to lymph nodes in resected NSCLC patients. J Cardiothorac Surg 2013, 8:63. BioMed Central Full Text
• [21]Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Holscher AH, Danenberg PV: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res 2001, 7(7):1850-1855.
• [22]Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, Kozower BD, Jones DR: Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. Eur J Cardiothorac Surg 2009, 35(4):699-705.
• [23]Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q: ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep 2012, 39(6):6933-6942.
• [24]Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD: p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 1997, 94(20):11037-11042.
• [25]Nakamura H, Hirata T, Kitamura H, Nishikawa J: Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers. Ann Thorac Cardiovasc Surg 2009, 15(5):304-310.